KRYSTEXXA
Drug
Amgen Inc.
Total Payments
$124.7M
Transactions
195,578
Doctors
32,183
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $61.6M | 41,631 | 12,883 |
| 2023 | $13.2M | 35,487 | 11,083 |
| 2022 | $13.8M | 31,406 | 8,825 |
| 2021 | $11.0M | 25,126 | 7,316 |
| 2020 | $10.5M | 14,669 | 4,646 |
| 2019 | $8.3M | 20,024 | 7,400 |
| 2018 | $3.9M | 16,746 | 6,256 |
| 2017 | $2.5M | 10,489 | 4,176 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $90.9M | 828 | 72.9% |
| Honoraria | $18.4M | 9,448 | 14.7% |
| Food and Beverage | $4.8M | 171,831 | 3.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.2M | 1,605 | 2.5% |
| Travel and Lodging | $2.9M | 8,713 | 2.3% |
| Consulting Fee | $2.4M | 453 | 1.9% |
| Royalty or License | $2.0M | 2 | 1.6% |
| Grant | $200,594 | 6 | 0.2% |
| Education | $47,198 | 2,688 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $6,900 | 4 | 0.0% |
Payments by Type
Research
$90.9M
828 transactions
General
$33.9M
194,750 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| P4 Uncontrolled Gout FORWARD II | Amgen Inc. | $54.3M | 0 |
| INFUSION DURATION STUDY TO ASSESS TOLERABILITY OF PEGLOTICASE ADMINISTERED WITH A SHORTER INFUSION DURATION IN SUBJECTS WITH UNCONTROLLED GOUT RECEIVING METHOTREXATE | Horizon Therapeutics plc | $8.7M | 0 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, EFFICACY AND SAFETY STUDY OF METHOTREXATE TO INCREASE RESPONSE RATES IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING KRYSTEXXA? (PEGLOTICASE) (MIRROR RANDOMIZED CONTROLLED TRIAL [RCT]) | Horizon Therapeutics plc | $6.9M | 0 |
| A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER EFFICACY AND SAFETY STUDY OF METHOTREXATE TO INCREASE RESPONSE RATES IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING KRYSTEXXA (PEGLOTICASE) (MIRROR RANDOMIZED CONTROLLED TRIAL RCT ) | Horizon Therapeutics plc | $3.4M | 0 |
| A PHASE 1B, COMBINED SINGLE-DOSE AND MULTIPLE-DOSE, MULTICENTER, RANDOMIZED, OPEN-LABEL TRIAL TO ASSESS SAFETY AND TOLERABILITY OF TWO DIFFERENT DOSE LEVELS OF SUBCUTANEOUS PEGLOTICASE IN SUBJECTS WITH UNCONTROLLED GOUT RECEIVING METHOTREXATE | Horizon Therapeutics plc | $2.4M | 0 |
| A PHASE 4, OPEN-LABEL STUDY OF KRYSTEXXA? (PEGLOTICASE) CO-ADMINISTERED WITH METHOTREXATE (MTX) IN PATIENTS WITH UNCONTROLLED GOUT | Horizon Therapeutics plc | $1.6M | 0 |
| REDUCING IMMUNOGENICITY TO PEGLOTICASE RECIPE STUDY | Horizon Therapeutics plc | $1.2M | 0 |
| HZNP-KRY-405 | Horizon Therapeutics plc | $1.1M | 0 |
| A MULTICENTER, EFFICACY AND SAFETY STUDY OF METHOTREXATE TO INCREASE RESPONSE RATES IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING KRYSTEXXA PEGLOTICASE MIRROR OL | Horizon Therapeutics plc | $736,036 | 0 |
| A PHASE 4, OPEN-LABEL STUDY OF KRYSTEXXA (PEGLOTICASE) CO-ADMINISTERED WITH METHOTREXATE (MTX) IN PATIENTS WITH UNCONTROLLED GOUT | Horizon Therapeutics plc | $728,359 | 0 |
| P4 Uncontrolled Gout FORWARD | Amgen Inc. | $704,387 | 0 |
| A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF PEGLOTICASE IN PATIENTS WITH UNCONTROLLED GOUT WHO HAVE UNDERGONE KIDNEY TRANSPLANTATION | Horizon Therapeutics plc | $698,013 | 0 |
| A PHASE 4 OPEN-LABEL STUDY OF KRYSTEXXA (PEGLOTICASE) CO-ADMINISTERED WITH METHOTREXATE (MTX) IN PATIENTS WITH UNCONTROLLED GOUT | Horizon Therapeutics plc | $674,738 | 0 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, EFFICACY AND SAFETY STUDY OF METHOTREXATE TO INCREASE RESPONSE RATES IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING KRYSTEXXA PEGLOTICASE MIRROR RANDOMIZED CONTROLLED TRIAL RCT | Horizon Therapeutics plc | $593,671 | 0 |
| A PHASE 4, MULTICENTER, OPEN-LABEL, EFFICACY AND SAFETY TRIAL OF PEGLOTICASE AND METHOTREXATE CO-ADMINISTERED IN PATIENTS WITH UNCONTROLLED GOUT WHO HAVE PREVIOUSLY RECEIVED PEGLOTICASE MONOTHERAPY BUT DID NOT MAINTAIN A SERUM URIC ACID RESPONSE | Horizon Therapeutics plc | $529,156 | 0 |
| P4 Uncontrolled Gout AGILE | Amgen Inc. | $452,313 | 0 |
| A MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF PEGLOTICASE IN PATIENTS WITH UNCONTROLLED GOUT WHO HAVE UNDERGONE KIDNEY TRANSPLANTATION | Horizon Therapeutics plc | $443,188 | 0 |
| RECIPE | Horizon Pharma plc | $392,181 | 0 |
| A PHASE 1, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY TO COMPARE THE PHARMACOKINETICS OF PEGLOTICASE FOLLOWING SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATIONS IN ADULT SUBJECTS | Horizon Therapeutics plc | $372,876 | 0 |
| INVESTIGATOR-INITIATED RESEARCH | Horizon Therapeutics plc | $352,586 | 0 |
Top Doctors Receiving Payments for KRYSTEXXA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Birmingham, AL | $91.0M | 840 |
| , M.D., RPH | Rheumatology | Anchorage, AK | $1.9M | 694 |
| , MD | Rheumatology | Bothell, WA | $1.9M | 832 |
| , M.D | Rheumatology | Charlottesville, VA | $1.4M | 41 |
| , DPM | Foot & Ankle Surgery | Belleville, NJ | $958,618 | 1,293 |
| , M.D | Internal Medicine | Webster, TX | $638,364 | 736 |
| , D.O | Rheumatology | Fullerton, CA | $618,961 | 635 |
| , MD | Rheumatology | Concord, NC | $605,191 | 527 |
| , DO | Rheumatology | Austin, TX | $599,663 | 500 |
| , M.D | Nephrology | Poughkeepsie, NY | $581,278 | 718 |
| , MD | Rheumatology | Santa Monica, CA | $466,093 | 486 |
| , M.D | Rheumatology | Mayfield Village, OH | $380,899 | 436 |
| , M.D | Internal Medicine | Houston, TX | $372,233 | 498 |
| , DPM | Foot & Ankle Surgery | Mooresville, IN | $361,832 | 439 |
| , D.O | Rheumatology | Tifton, GA | $333,457 | 380 |
| , M.D | Hospitalist | Aventura, FL | $324,332 | 401 |
| , D.O | Rheumatology | Phoenix, AZ | $317,795 | 497 |
| , M. D | Internal Medicine | Houston, TX | $296,113 | 452 |
| , MD | Rheumatology | Glendale, WI | $292,526 | 464 |
| , MD | Internal Medicine | Pittsburgh, PA | $262,291 | 352 |
| , D.P.M | Podiatrist | Reisterstown, MD | $253,613 | 414 |
| , M.D | Rheumatology | Rochester Hills, MI | $250,337 | 331 |
| , MD | Rheumatology | Saint Clair Shores, MI | $244,214 | 321 |
| , D.O | Rheumatology | Warren, MI | $202,073 | 198 |
| , M.D | Rheumatology | West Hollywood, CA | $200,487 | 273 |
Ad
Manufacturing Companies
- Amgen Inc. $61.6M
- Horizon Therapeutics plc $56.8M
- Horizon Pharma plc $6.4M
Product Information
- Type Drug
- Total Payments $124.7M
- Total Doctors 32,183
- Transactions 195,578
About KRYSTEXXA
KRYSTEXXA is a drug associated with $124.7M in payments to 32,183 healthcare providers, recorded across 195,578 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2017 to 2024. In 2024, $61.6M was paid across 41,631 transactions to 12,883 doctors.
The most common payment nature for KRYSTEXXA is "Unspecified" ($90.9M, 72.9% of total).
KRYSTEXXA is associated with 20 research studies, including "P4 Uncontrolled Gout FORWARD II" ($54.3M).